Skip to main content
. 2020 Jun 19;39(31):5373–5389. doi: 10.1038/s41388-020-1364-7

Fig. 5. Expression of constitutively active KRAS restores both TAZ protein levels and the abilities to form xenograft tumors of MiaPaCa2 and MDA-MB231 cells with silenced ICMT.

Fig. 5

Tumor formation study using MiaPaCa2 (a, b) and MDA-MB231 (c, d) cells. For this study, 80,000 cancer cells either expressing CA-KRAS or control vector, in the presence or absence of ICMT knockdown, were injected subcutaneously into NOD-SCID mice; n = 10 tumors were implanted for each cell group. The mice were sacrificed and tumors excised when any tumor reached size limit set by the IACUC protocol. The images of the tumors derived from MiaPaCa2 and MDA-MB231 cell are shown in a and c, respectively. The percentages of tumor-free mice over the course of the experiment are plotted in b and d for the study groups of a and c, respectively. e Immunoblot analysis of TAZ protein levels for the tumor samples in a and c, respectively. f Immunofluorescent analysis of TAZ protein using the tumor samples from a.